Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2020-11-26
2022-11-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Epithelial ovarian cancer patients sensitive to platinum based chemotherapy
Homologous recombination deficiency model
A homologous recombination deficiency (HRD) scoring model based on loss of heterozygosity (LOH)
Epithelial ovarian cancer patients resistant to platinum based chemotherapy
Homologous recombination deficiency model
A homologous recombination deficiency (HRD) scoring model based on loss of heterozygosity (LOH)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Homologous recombination deficiency model
A homologous recombination deficiency (HRD) scoring model based on loss of heterozygosity (LOH)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Pathological confirmation of epithelial ovarian cancer
* With available tumor tissues
* Given consents to participate the study
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lei Li
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lei Li
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lei Li, M.D.
Role: PRINCIPAL_INVESTIGATOR
Peking Union Medical College Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lei Li
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Lei Li, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EOC-LOH
Identifier Type: -
Identifier Source: org_study_id